VBL to stop developing drug for psoriasis, ulcerative colitis

Reuters Health Information: VBL to stop developing drug for psoriasis, ulcerative colitis

VBL to stop developing drug for psoriasis, ulcerative colitis

Last Updated: 2015-02-17

By Reuters Staff

(Reuters) - Israel's VBL Therapeutics Inc said it would stop developing its experimental inflammatory drug to fight ulcerative colitis and psoriasis, sending its shares tumbling 45% before the bell.

The company said the drug, VB-201, failed to meet the main goal in separate mid-stage trials for the two indications.

VB-201 aims to treat chronic immune-inflammatory diseases by mimicking the body's natural anti-inflammatory response.

Separately, the biotechnology company said the U.S. Food and Drug Administration lifted a partial hold on another drug that is being tested to treat an aggressive form of brain cancer.

The biotech drug, VB-111, will be evaluated in a late-stage study in patients with recurrent glioblastoma. The hold was imposed by the agency in July, pending additional data.

VB-111 is also being tested to fight ovarian cancer and the most common form of thyroid cancer.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.